Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of goods sold | 461,689 | 438,255 | 864,095 | 877,784 |
| Gross profit | 334,508 | 286,253 | 654,621 | 542,144 |
| Selling, general and administrative | 148,722 | 124,266 | 287,582 | 242,554 |
| Research and development | 39,017 | 47,964 | 77,400 | 88,004 |
| Intellectual property legal development expenses | 2,087 | 2,017 | 3,629 | 3,784 |
| Acquisition costs | 7,600 | — | 12,753 | — |
| Restructuring and other charges | 554 | 1,024 | 1,204 | 1,595 |
| Charges (credit) related to legal matters, net | 8,057 | (390) | 8,751 | (390) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s R&D?
- Amneal Pharmaceuticals, Inc. (AMRX) reported R&D of $39.02M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s R&D changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s R&D decreased by 18.7% year-over-year, from $47.96M to $39.02M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s R&D?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s R&D has grown at a -2.0% compound annual growth rate (CAGR), from $201.85M to $186.18M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Amneal Pharmaceuticals, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude